Intercept receives orphan drug designation for liver disease combo therapy
The FDA granted orphan drug status to Intercept’s therapy, which combines the approved Ocaliva with another drug called bezafibrate.
Source: pharmaceutical-technology.com
Pharma Intelligence Centre News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharma Intelligence Centre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharma Intelligence Centre Today - Breaking & Trending Today
Valneva's Lyme disease vaccine faces final clinical test in a sparse landscape
VLA15 could tip the scales against Lyme disease, but public perception of tick-borne disease vaccines remains critical
Source: pharmaceutical-technology.com
Regulatory and strategic complications of oncology drug marketing in Asia
By GlobalData Healthcare 06 May 2021 (Last Updated May 6th, 2021 14:34) The US is the most lucrative market for prescription drugs, routinely generating more than 50% of global sales in multiple therapy areas, including oncology. In the past five years, the Food and Drug Administration (FDA) has approved 88 innovator or new formulation drugs in oncology, few of which have made it into Japan and even fewer into China. Share Article The US is the most lucrative market for prescription drugs, routinely generating more than 50% o...
Source: pharmaceutical-technology.com